Oral ciclopirox for skin sensitivity in CEP
Part of Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This trial tests an oral medication called ciclopirox (ATL-001) to see if it can reduce skin sensitivity to sunlight in adults with CEP. It aims to improve the skin lesions caused by this rare disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years of age or older.
- You must have a confirmed diagnosis of Congenital Erythropoietic Porphyria (CEP).
- If you are a woman who could become pregnant, you must not be pregnant or breastfeeding, and you must agree to use two reliable forms of birth control.
- If you are a man with a partner who could become pregnant, you must agree to use effective birth control and not donate sperm.
- You cannot have other skin conditions that cause sun sensitivity, like solar urticaria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how your body reacts to sunlight if you have erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP)—rare genetic conditions that cause painful skin reactions to sun exposure. Researchers will use special devices and daily logs to better understand your symptoms and how light affects your skin.
This trial checks the long-term safety and side effects of an oral medicine called dersimelagon in people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP). It is mainly for people who have already finished an earlier dersimelagon study and are able to keep coming to clinic visits.
This trial tests an oral drug called erlotinib (an EGFR inhibitor) in adults with certain genetic skin disorders. It aims to reduce symptoms of thickened, blistering or scaly skin. You may be able to join if you have a confirmed genetic form of these conditions and your skin is moderately affected.
This program provides access to bitopertin, an experimental medicine being tested for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)—rare genetic conditions affecting how your body processes heme, a component of blood. The program aims to offer the medication to eligible patients while safety is being studied.
This trial studies how safe and well bitopertin works over the long term for people with EPP. It mainly includes people who already finished an earlier bitopertin study, to keep tracking side effects and overall progress.
This study tests a new drug called EPN-701 for calciphylaxis, a serious condition where calcium deposits damage blood vessels and skin, causing painful sores. If you have this condition and are on regular dialysis, this trial may help reduce your pain and heal your wounds.
Hear when a new Congenital Erythropoietic Porphyria (CEP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.